This paper was miscategorized in the March 2021 issue and should have been included under the subject category of Pharmaceutical Biotechnology with the companion article, “Mechanism of Thimerosal-Induced Structural Destabilization of a Recombinant Rotavirus P[4] Protein Antigen Formulated as a Multi-Dose Vaccine” [J Pharm Sci 110 (2021) 1054–1066].
. 2021 Apr;110(4):1867. doi: 10.1016/j.xphs.2021.03.003
Erratum to “Rapid developability assessments to formulate recombinant protein antigens as stable, low-cost, multi-dose vaccine candidates: Case-study with non-replicating rotavirus (NRRV) vaccine antigens” [J Pharm Sci 110 (2021) 1042–1053]
© 2021 American Pharmacists Association. Published by Elsevier Inc.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
PMCID: PMC8445825 PMID: 33662392
This corrects the article "Rapid Developability Assessments to Formulate Recombinant Protein Antigens as Stable, Low-Cost, Multi-Dose Vaccine Candidates: Case-Study With Non-Replicating Rotavirus (NRRV) Vaccine Antigens" on page 1042.
This corrects the article "Mechanism of Thimerosal-Induced Structural Destabilization of a Recombinant Rotavirus P[4] Protein Antigen Formulated as a Multi-Dose Vaccine" on page 1054.